Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests £230
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  3. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  4. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  5. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  6. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  7. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  8. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  9. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  10. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  11. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  12. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  13. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  14. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  15. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  16. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  17. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  18. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  19. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  20. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  21. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  22. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  23. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  24. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  25. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  26. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  27. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  28. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  29. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  30. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  31. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  32. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  33. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  34. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  35. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  36. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  37. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  38. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  39. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  40. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  41. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  42. Pleuger C, et al. 2022. Elife. 11: . PubMed
  43. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  44. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  45. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  46. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  47. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  48. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  49. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  50. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  51. Rosain J, et al. 2023. Cell. 186:621. PubMed
  52. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  53. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  54. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  55. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  56. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  57. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  58. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  59. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  60. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  61. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  62. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  63. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  64. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  65. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  66. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  67. Zhao Y, et al. 2022. J Neurosci. . PubMed
  68. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  69. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  70. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  71. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  72. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  73. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  74. Han X, et al. 2022. Nutrients. 14:. PubMed
  75. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  76. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  77. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  78. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  79. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  80. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  81. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  82. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  83. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  84. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  85. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  86. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  87. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  88. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  89. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  90. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  91. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  92. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  93. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  94. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  95. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  96. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  97. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  98. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  99. Imai H, et al. 2023. iScience. 26:106822. PubMed
  100. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  101. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  102. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  103. Wu L, et al. 2023. Cell Res. . PubMed
  104. Cansever D, et al. 2023. Nat Immunol. . PubMed
  105. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  106. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  107. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  108. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  109. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  110. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  111. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  112. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  113. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  114. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  115. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  116. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  117. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  118. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  119. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  120. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  121. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  122. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  123. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  124. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  125. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  126. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  127. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  128. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  129. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  130. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  131. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  132. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  133. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  134. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  135. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  136. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  137. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  138. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  139. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  140. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  141. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  142. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  143. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  144. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  145. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  146. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  147. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  148. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  149. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  150. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  151. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  152. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  153. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  154. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  155. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  156. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  157. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  158. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  159. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  160. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  161. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  162. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  163. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  164. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  165. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  166. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  167. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  168. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  169. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  170. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  171. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  172. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  173. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  174. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  175. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  176. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  177. Woodruff MC, et al. 2022. Nature. :. PubMed
  178. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  179. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  180. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  181. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  182. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  183. Akiyama H, et al. 2020. J Virol. . PubMed
  184. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  185. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  186. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  187. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  188. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  189. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  190. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  191. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  192. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  193. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  194. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  195. Mills C, et al. 2022. Cells. 11:. PubMed
  196. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  197. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  198. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  199. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  200. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  201. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  202. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  203. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  204. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  205. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  206. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  207. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  208. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  209. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  210. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  211. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  212. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  213. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  214. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  215. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  216. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  217. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  218. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  219. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  220. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  221. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  222. Wang Z, et al. 2021. bioRxiv. . PubMed
  223. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  224. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  225. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  226. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  227. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  228. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  229. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  230. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  231. English KG, et al. 2022. Biomedicines. 10:. PubMed
  232. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  233. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  234. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  235. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  236. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  237. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  238. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  239. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  240. Woodruff M, et al. 2020. medRxiv. . PubMed
  241. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  242. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  243. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  244. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  245. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  246. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  247. Popay TM, et al. 2021. Elife. 10: . PubMed
  248. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  249. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  250. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  251. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  252. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  253. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  254. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  255. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  256. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  257. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  258. Elias G, et al. 2022. Elife. 11:. PubMed
  259. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  260. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  261. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  262. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  263. Ito Y, et al. 2018. Cell. 174:636. PubMed
  264. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  265. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  266. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  267. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  268. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  269. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  270. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  271. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  272. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  273. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  274. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  275. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  276. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  277. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  278. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  279. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  280. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  281. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  282. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  283. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  284. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  285. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  286. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  287. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  288. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  289. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  290. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  291. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  292. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  293. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  294. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  295. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  296. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  297. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  298. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  299. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  300. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  301. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  302. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  303. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  304. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  305. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  306. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  307. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  308. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  309. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  310. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  311. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  312. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  313. Wang Z, et al. 2021. Nature. 592:616. PubMed
  314. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  315. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  316. Dudek M, et al. 2021. Nature. 592:444. PubMed
  317. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  318. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  319. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  320. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  321. He Y, et al. 2022. Cells. 11:. PubMed
  322. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  323. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  324. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  325. Wang Z, et al. 2021. Nature. 595:426. PubMed
  326. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  327. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  328. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  329. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  330. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  331. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  332. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  333. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  334. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  335. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  336. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  337. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  338. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  339. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  340. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  341. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  342. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  343. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  344. Korin B, et al. 2020. Sleep. :43. PubMed
  345. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  346. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  347. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  348. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  349. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  350. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  351. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  352. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  353. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  354. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  355. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  356. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  357. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  358. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  359. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  360. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  361. Viant C, et al. 2020. Cell. 183:1298. PubMed
  362. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  363. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  364. Gaebler C, et al. 2020. bioRxiv. . PubMed
  365. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  366. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  367. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  368. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  369. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  370. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  371. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  372. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  373. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  374. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  375. Sibler E, et al. 2021. Cells. 10:. PubMed
  376. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  377. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  378. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  379. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  380. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  381. Spath S, et al. 2022. iScience. 25:104998. PubMed
  382. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  383. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  384. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  385. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  386. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  387. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  388. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  389. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  390. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  391. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  392. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  393. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  394. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  395. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  396. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  397. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  398. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  399. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  400. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account